Nucleic Acid Based Gene Therapy Market Revenue Anticipated To Reach $1.43 Billion By 2030 With 10.4% CAGR
The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Forecasted Rise In Market Size Of The Nucleic Acid Based Gene Therapy Market During The Forecast Period?
The nucleic acid based gene therapy market size has seen rapid expansion in recent years. It is projected to increase from $0.88 billion in 2025 to $0.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.2%. This historical growth can be ascribed to advancements in molecular biology research, a deeper understanding of genetic disease mechanisms, the expansion of clinical trials for gene therapies, rising investment in biotechnology research, and early regulatory approvals for nucleic acid therapies.
The nucleic acid based gene therapy market size is anticipated to experience substantial growth in the coming years. It is projected to reach $1.44 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.4%. This expansion during the forecast period is driven by factors such as the increasing adoption of CRISPR-based treatments, a rising demand for therapies for rare diseases, the growth of gene therapy manufacturing facilities, a heightened focus on personalized oncology treatments, and increasing public and private funding for genetic medicine. Significant trends expected during this period include the growing uptake of RNA-based therapeutics, an increased utilization of viral and non-viral gene delivery systems, a stronger emphasis on targeted gene editing technologies, the expansion of personalized genetic therapies, and an enhanced focus on precision medicine applications.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp
What Market Drivers Are Helping Shape The Nucleic Acid Based Gene Therapy Market Expansion?
The escalating financial backing from governments and private enterprises is poised to fuel the expansion of the nucleic acid based gene therapy market in the foreseeable future. This financial assistance refers to monetary investments, grants, or subsidies originating from public or private institutions, designed to advance the research, development, and commercialization of these therapies. The surge in financial support is attributed to an increasing worldwide emphasis on developing treatments for rare and genetic diseases that currently lack effective remedies. Government funding specifically for nucleic-acid–based gene therapy accelerates progress by supplying crucial resources for research, clinical trials, and infrastructure, thereby directly driving innovation and the translation of discoveries into effective treatments. For example, in July 2023, the U.S. National Institutes of Health, a U.S.-based federal health research agency, awarded over $140 million to expedite genome editing approaches, including CRISPR and other nucleic acid technologies, for rare neurological and blood disorders, which marks a significant increase compared to the previous annual funding of $92 million in 2022. Therefore, the heightened financial support from governments and companies is a key driver for the growth of the nucleic acid based gene therapy market.
What Are The Major Segment Categories Within The Nucleic Acid Based Gene Therapy Market?
The nucleic acid based gene therapy market covered in this report is segmented –
1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies
2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases
3) By End User: Hospitals And Clinics, Academic And Research Institutes
Subsegments:
1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)
2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies
3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)
4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs
5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes
6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers
7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)
What Trends Are Influencing The Nucleic Acid Based Gene Therapy Market?
Leading companies operating in the nucleic acid-based gene therapy market are primarily focused on personalized, autologous stem-cell treatments, such as genetically modified hematopoietic stem-cell infusions, for the management of rare inherited diseases. Autologous therapies involve the removal of a patient’s own stem cells, which are then genetically corrected and re-infused to restore the missing biochemical function. For instance, in March 2024, Orchard Therapeutics, a US-based company offering pharmaceuticals, announced that Lenmeldy (atidarsagene autotemcel) had been approved by the U.S. Food and Drug Administration for use in children with metachromatic leukodystrophy (MLD). Lenmeldy utilizes the patient’s own hematopoietic stem cells, which are genetically modified to express a functional ARSA gene, thereby enabling enzyme restoration in the nervous system. This regulatory success highlights the capability of companies to commercialize intricate, autologous gene therapies despite facing high manufacturing costs.
Which Companies Form The Competitive Landscape Of The Nucleic Acid Based Gene Therapy Market?
Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.
Access The Complete Nucleic Acid Based Gene Therapy Market Report:
Which Region Is The Dominant Market In The Nucleic Acid Based Gene Therapy Market?
North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Nucleic Acid Based Gene Therapy Market Report for Deeper Competitive Insights
Browse Through More Reports Similar to the Global Nucleic Acid Based Gene Therapy Market 2026, By The Business Research Company
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Cell And Gene Therapy Clinical Trial Services Market Report 2026
Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
